Surfactant use in late preterm infants: a survey among Belgian neonatologists
- PDF / 526,293 Bytes
- 8 Pages / 595.276 x 790.866 pts Page_size
- 116 Downloads / 157 Views
ORIGINAL ARTICLE
Surfactant use in late preterm infants: a survey among Belgian neonatologists L. Cornette 1
&
A. Mulder 2 & A. Debeer 3 & G. Malfilâtre 4 & V. Rigo 5 & F. Cools 6 & O. Danhaive 7,8
Received: 30 July 2020 / Revised: 5 September 2020 / Accepted: 8 September 2020 # Springer-Verlag GmbH Germany, part of Springer Nature 2020
Abstract Specific recommendations on surfactant administration in late preterm (LPT) infants with pulmonary disease are lacking. We performed an online-based, nationwide survey amongst all (n = 102) Belgian neonatologists to identify the use of surfactant in LPT infants suffering from several respiratory pathologies. The survey used clearly defined clinical cases and resulted in a 86% response rate. Neonatologists adhere to the 200 mg/kg initial surfactant dosing scheme. Surfactant is widely used in respiratory distress syndrome (70.1%), but there is less unanimity on its use in meconium aspiration syndrome (58.0%), transient tachypnoea of the newborn (30.6%), congenital pneumonia (27.2%) and congenital diaphragmatic hernia (8.6%). Respondents adhere to the European guideline of a timely referral to a newborn intensive care unit (non-invasive ventilation and FiO2 > 0.30 at 12 h of age), in order to minimise the risk of deterioration. Conclusion: We demonstrate a wide variety in the use of surfactant within LPT infants. The majority of Belgian neonatologists therefore urge for an investment in multi-centre trials on surfactant administration in LPT infants, in order to create an evidencebased practice as well as to reduce the strain on health care budgets. Trial registration: https://clinicaltrials.gov What is Known: • Any late preterm (LPT) infant with respiratory distress needs a timely referral to a neonatal intensive care unit in case of non-invasive ventilation and FiO2 > 0.30 at 12 h of life, in order to minimise the risk of acute deterioration as well as chronic lung disease. • Any modest increase in morbidity in the sizeable group of LPT infants exerts a significant strain on health care budgets. What is New: • We report the attitudes and opinions of Belgian neonatologists about the use of surfactant in LPT infants suffering from several respiratory diseases. • Our survey demonstrates a significant variability in practice between neonatologists during treatment of respiratory pathologies in LPT infants. This highlights an urgent need for univocal therapeutic lines. Communicated by Daniele De Luca * L. Cornette [email protected] A. Mulder [email protected] A. Debeer [email protected] G. Malfilâtre [email protected] V. Rigo [email protected]
1
AZ St-Jan Brugge, Ruddershove 10, 8000 Bruges, Belgium
2
UZ Antwerpen, Wilrijkstraat 10, 2650 Edegem, Belgium
3
UZ Leuven, Herestraat 49, 3000 Leuven, Belgium
4
CHU Tivoli, Avenue Max Buset 34, 7100 La Louvière, Belgium
5
CHU de Liège, Boulevard du Douzième de Ligne 1, 4000 Liège, Belgium
6
UZ Brussel, Avenue du Laerbeek 101, 1090 Jette, Belgium
7
UC Louvain, Place de l’Universit
Data Loading...
